Alimentary Pharmacology & Therapeutics最新文献

{"title":"Lymphocyte‐to‐Monocyte Ratio as a Predictor of Recompensation in Patients With Decompensated Primary Biliary Cholangitis","authors":"Huiying Lin, Mengyao Zheng, Yaqin Huang, Huilin Zhu, Lili Zhang, Wenting Yang, Hongjin Wang, Tingting Yin, Min Zhou, Hongtao Lei, Wenlin Tai, Jinhui Yang","doi":"10.1111/apt.70233","DOIUrl":"https://doi.org/10.1111/apt.70233","url":null,"abstract":"BackgroundPrimary biliary cholangitis (PBC) patients in the decompensated stage face poor prognoses, with recompensation being crucial for improving long‐term outcomes.AimThis study aims to evaluate the predictive value of the lymphocyte‐to‐monocyte ratio (LMR) for recompensation in decompensated PBC patients.MethodsWe retrospectively analysed 410 patients with PBC‐related decompensated cirrhosis receiving ursodeoxycholic acid (UDCA) treatment. The association between the LMR and recompensation was examined using Cox regression analysis, with additional trend analysis performed based on LMR quartiles. The predictive accuracy of the LMR, neutrophil‐to‐lymphocyte ratio (NLR), systemic immune‐inflammation index (SII) and platelet‐to‐lymphocyte ratio (PLR) was evaluated using receiver operating characteristic (ROC) curve analysis. Sensitivity analyses were conducted to confirm the robustness of the findings.ResultsDuring follow‐up, among 401 patients with decompensated cirrhosis (age: 60.0 [IQR: 53.0–69.0] years; 88.3% female), 105 patients (26.18%) achieved recompensation. Multivariate Cox regression analysis showed that higher LMR was an independent promoting factor for recompensation after adjusting for all confounding factors in the model (HR = 1.415, 95% CI: 1.264–1.585, <jats:italic>p</jats:italic> &lt; 0.001), with a linear positive correlation trend. ROC curve analysis demonstrated that LMR had superior predictive performance compared to other inflammatory markers (SII, PLR, NLR), with an area under the curve (AUC) of 0.787 (95% CI: 0.736–0.838, <jats:italic>p</jats:italic> &lt; 0.001).ConclusionLMR serves as a robust independent predictor for recompensation in decompensated PBC patients.","PeriodicalId":121,"journal":{"name":"Alimentary Pharmacology & Therapeutics","volume":"25 1","pages":""},"PeriodicalIF":7.6,"publicationDate":"2025-06-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144340834","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical Utility and Cost‐Effectiveness of Pretreatment NUDT15 Pharmacogenetic Testing to Prevent Thiopurine‐Induced Myelosuppression: A Genotype‐First Reverse Phenotyping Cohort Study Within the UK NIHR Inflammatory Bowel Disease Bioresource","authors":"Christopher Roberts, Jaime Peters, Aleksejs Sazonvos, Neil Goodman, Mohmmed Sharip, Rebecca Smith, Maria Bishara, Claire Bewshea, Simeng Lin, Neil Chanchlani, Phoebe Hodges, Fakhirah Badrulhisham, Aamir Saifuddin, Sean Carlson, Andrea Centritto, Alexandra Marley, Muhammad Saad, Karishma Sethi‐Aora, Laura White, Alaa Abdelmeguid, Laetitia Pele, Shaji Sebastian, Christian Selinger, Peter Irving, Laura Fachal, Gareth Walker, Rachel Palmer, Nick Kennedy, Jayne Houghton, Chris Hyde, Miles Parkes, James Goodhand, Tariq Ahmad","doi":"10.1111/apt.70232","DOIUrl":"https://doi.org/10.1111/apt.70232","url":null,"abstract":"BackgroundThe clinical utility and cost‐effectiveness of pre‐thiopurine <jats:italic>NUDT15</jats:italic> pharmacogenetic testing in European and admixed populations are unknown.AimsTo report the prevalence, penetrance, expressivity, and pathogenicity of <jats:italic>NUDT15</jats:italic> variant allele carriage and the diagnostic accuracy and cost‐effectiveness of an inexpensive loop‐mediated isothermal amplification (LAMP) test.MethodsRetrospective case‐matched cohort study of rates of severe myelosuppression in patients with and without loss‐of‐function <jats:italic>NUDT15</jats:italic> variant allele(s) treated with a thiopurine.ResultsOverall, 1.3% of Europeans and 11.7% of South Asians carried a variant allele. Severe myelosuppression was associated with <jats:italic>NUDT15</jats:italic> variant allele carriage (11.3% vs 0.95%; <jats:italic>p</jats:italic> &lt; 0.001). Carriage of a single *3, *6 or *9 variant allele was associated with a shorter time to severe myelosuppression. Numbers needed to genotype to prevent myelosuppression in Europeans and South Asians were 786 and 23. Variant calling using the LAMP assay was fully concordant with Sanger sequencing (<jats:italic>n</jats:italic> = 154). It improved the safety of thiopurine dosing and was cost‐effective when used to reduce the frequency and cost of thiopurine blood monitoring for patients without risk variants.ConclusionWe recommend <jats:italic>TPMT</jats:italic> and <jats:italic>NUDT15</jats:italic> genetic testing in patients of Asian and admixed ancestry. In Europeans, reflex <jats:italic>NUDT15</jats:italic> testing should be considered in patients with reduced TPMT activity or loss‐of‐function genotype. Thiopurines should be avoided in patients with &gt; 1 <jats:italic>NUDT15</jats:italic> variant allele and in patients with both <jats:italic>NUDT15</jats:italic> and <jats:italic>TPMT</jats:italic> variant alleles. In patients with a single <jats:italic>NUDT15</jats:italic> variant allele, we recommend thiopurine dose reduction (&lt; 1 mg/kg/day) and intensified blood test monitoring.","PeriodicalId":121,"journal":{"name":"Alimentary Pharmacology & Therapeutics","volume":"12 1","pages":""},"PeriodicalIF":7.6,"publicationDate":"2025-06-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144340812","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Combined Lyon and Milan Scores Predict Gerd Management Outcome Better Than Either Score Alone or Their Individual Components","authors":"Stefano Siboni, Marco Sozzi, Pierfrancesco Visaggi, Sara Boveri, Benjamin D. Rogers, Nicola De Bortoli, Anthony Hobson, Brian E. Louie, Yeong Yeh Lee, Salvatore Tolone, Elisa Marabotto, Jordan Haworth, Megan L. Ivy, Lorenzo Cusmai, Edoardo Campioli, Dimitrios Theodorou, Tania Triantafyllou, Andrea Pasta, Francesco Calabrese, Vincent Tee, Daniele Bernardi, Carlo Galdino Riva, Roberta De Maron, Enrique Coss‐Adame, Amit Patel, Emanuele Asti, Edoardo Savarino, C. Prakash Gyawali","doi":"10.1111/apt.70245","DOIUrl":"https://doi.org/10.1111/apt.70245","url":null,"abstract":"BackgroundConfidence in gastro‐oesophageal reflux disease (GERD) diagnosis is crucial to improve outcomes from escalation of treatment. The Lyon score phenotypes patients through endoscopy and pH‐impedance (MII‐pH). The Milan score quantifies antireflux barrier through high‐resolution manometry (HRM) parameters.AimTo explore the relationship between the Lyon and Milan scores and their combined performance in predicting clinical outcomes.MethodsWe collected clinical and follow‐up data of consecutive patients with HRM and MII‐pH from nine centres. Clinical improvement was defined as a 50% reduction in global symptoms. The relationship between Lyon and Milan scores and the rate of patients improved in Lyon phenotypes and Milan categories were explored. The ability of the Lyon, Milan, DeMeester scores and acid exposure time (AET) in predicting outcomes was assessed through receiver operating characteristics (ROC) analysis.ResultsAmong 532 patients (50.6% female, age 50 years), 47.7% had pathologic GERD. A stepwise increase in the Milan score in Lyon phenotypes was observed. Sixty‐three patients had surgical treatment, and 131 medical. Clinical improvement in Lyon phenotypes Conclusive and Severe was 81% and 83%; in Milan categories very likely and extremely likely was 88.5% and 100%. If Lyon and Milan scores were positive, improvement was 89%; if discordant, 63%; if both negative, 19% (<jats:italic>p</jats:italic> &lt; 0.001). ROC analysis showed an AUC of 0.790 for Lyon score, 0.835 for Milan score, 0.736 for DeMeester score and 0.741 for AET.ConclusionsThe Lyon and Milan scores outperformed AET and DeMeester scores in predicting outcomes in GERD patients. When concordant, they provide optimal predictive accuracy, guiding escalation of therapy.","PeriodicalId":121,"journal":{"name":"Alimentary Pharmacology & Therapeutics","volume":"14 1","pages":""},"PeriodicalIF":7.6,"publicationDate":"2025-06-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144334838","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Azathioprine or Tofacitinib as Maintenance Therapy in Corticosteroid‐Responsive Acute Severe Ulcerative Colitis","authors":"Arshdeep Singh, Arshia Bhardwaj, Riya Sharma, Dharmatma Singh, Devanshi Jain, Namita Bansal, Gursimran Singh Kochhar, Vandana Midha, Ajit Sood","doi":"10.1111/apt.70246","DOIUrl":"https://doi.org/10.1111/apt.70246","url":null,"abstract":"BackgroundThe optimal maintenance therapy for patients with acute severe ulcerative colitis (ASUC) remains unclear.AimTo evaluate the efficacy of azathioprine and tofacitinib in maintaining remission in patients with ASUC who respond to intravenous corticosteroids.MethodsThis propensity score–matched, retrospective cohort study evaluated the effectiveness and safety of azathioprine and tofacitinib as maintenance therapies in adult patients with ASUC responding to intravenous corticosteroids. We recorded rehospitalisation, corticosteroid reuse, therapeutic escalation, and colectomy. The primary endpoint was cumulative event‐free survival at 1 year. Adverse events were documented in both treatment arms.ResultsWe included 115 patients in the final analysis (median age: 38 years [IQR: 28–49]; 54 females [46.95%]; 65 on azathioprine, 50 on tofacitinib). The cumulative probability of event‐free survival at 1 year was 44.0% with azathioprine and 75.0% with tofacitinib (log‐rank <jats:italic>p</jats:italic> = 0.01). Rates of rehospitalisation (15.4% v. 0%; <jats:italic>p</jats:italic> = 0.003) and therapeutic escalation (13.8% v. 2.0%; <jats:italic>p</jats:italic> = 0.02) were significantly greater in the azathioprine group. More patients receiving tofacitinib achieved symptomatic remission (40.0% v. 23.1%; <jats:italic>p</jats:italic> = 0.05), and combined symptomatic and biomarker remission (22.0% v. 16.9%; <jats:italic>p</jats:italic> = 0.49) at 1 year than those receiving azathioprine. Adverse events were reported in 55 patients (47.8%). No patients in either group required discontinuation of therapy due to adverse events.ConclusionTofacitinib is more effective than azathioprine as maintenance therapy for steroid‐responsive ASUC at 1 year.","PeriodicalId":121,"journal":{"name":"Alimentary Pharmacology & Therapeutics","volume":"12 1","pages":""},"PeriodicalIF":7.6,"publicationDate":"2025-06-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144328610","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Surviving Hepatitis C-Understanding Death and Survival Beyond Cure.","authors":"Paul J Clark,Patricia C Valery,Simone I Strasser,Martin Weltman,Alex Thompson,Miriam T Levy,Barbara Leggett,Amany Zekry,Y Julian Rong,Marie Sinclair,Jacob George,William Sievert,Gerry MacQuillan,Edmund Tse,Amanda Wade,Wendy Cheng,Stuart K Roberts","doi":"10.1111/apt.70219","DOIUrl":"https://doi.org/10.1111/apt.70219","url":null,"abstract":"BACKGROUND AND AIMSCure of hepatitis C virus (HCV) infection decreases liver- and all-cause mortality. However, the risk of early mortality after HCV cure remains. We examined factors associated with cause-specific mortality after direct-acting antiviral (DAA) therapy.METHODSDAA-treated adults (recruited 2016-2021) were followed up to September 2023. Medication, health-service use, and deaths were obtained from population databases. The primary outcome was all-cause and cause-specific mortality.RESULTSAmong 3619 patients (average 52.0 years (SD = 10.5), 66.0% male, 33.6% with cirrhosis) followed for a median of 6.8 years (IQR 5.5-7.4), 423 (11.7%) died (40.6% due to liver disease, 13.2% self-harm/accidental poisoning and 12.3% respiratory disease/lung cancer). Cirrhosis (adjusted hazard ratio (adj-HR) = 14.51, 95% CI 6.87-30.64), FIB4 > 3.25 (adj-HR = 4.22, 95% CI 2.63-6.80), nonsustained virological response (SVR) (adj-HR = 3.94, 95% CI 2.64-5.88) and age ≥ 60 years (adj-HR = 1.88, 95% CI 1.32-2.69) increased liver-related mortality risk. Mortality was threefold higher in non-SVR (32.4% of 210 patients vs. 10.2% of 2894 with SVR, p < 0.001). Non-SVR increased risk of liver mortality (adj-HR = 4.30, 95% CI 2.90-6.37). Mental health medication use (adj-HR = 2.82, 95% CI 1.40-5.67), loss to clinical follow-up (adj-HR = 2.61, 95% CI 1.31-5.21) and injection drug use/opioid replacement therapy (adj-HR = 2.26, 95% CI 1.23-4.14) increased risk of self-harm/accidental poisoning-related mortality. Age ≥ 60 years and diabetes increased mortality risk from other extrahepatic cancer (adj-HR = 2.68, 95% CI 1.31-5.51 and adj-HR = 2.57, 95% CI 1.15-5.72) and cardiovascular disease (adj-HR = 2.71, 95% CI 1.06-4.19 and adj-HR = 2.28, 95% CI 1.03-5.05).CONCLUSIONSLiver-related death drives mortality for cirrhotic patients. Curing HCV remains critical. Holistic HCV care, with attention to mental health illnesses in younger patients, metabolic comorbidities, and better cancer screening for older patients may reduce excess mortality.","PeriodicalId":121,"journal":{"name":"Alimentary Pharmacology & Therapeutics","volume":"1 1","pages":""},"PeriodicalIF":7.6,"publicationDate":"2025-06-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144320342","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Systematic Review: Variability in Definitions of Fibrostenosis in Eosinophilic Oesophagitis.","authors":"Claire A Beveridge,Natalie Farha,Christina Hermanns,Chiara Maruggi,Katherine Falloon,Shivani Thanawala,Mary Pat Harnegie,J Mark Brown,Andrei I Ivanov,Evan S Dellon,Gary W Falk,Christopher Ma,Nirmala Gonsalves,Anthony Lembo,Amanda B Muir,Scott Gabbard,Glenn T Furuta,Florian Rieder","doi":"10.1111/apt.70187","DOIUrl":"https://doi.org/10.1111/apt.70187","url":null,"abstract":"BACKGROUNDFibrostenosis is a serious complication of eosinophilic oesophagitis, but there is a lack of consensus regarding its definition and assessment. This poses a barrier in clinical care and research.AIMTo perform a systematic review to examine existing definitions and diagnostic methods of detection regarding fibrostenosis in eosinophilic oesophagitis.METHODSWe searched MEDLINE, Cochrane Library, EMBASE, Scopus, and Web of Science and included studies of paediatric and adult eosinophilic oesophagitis patients with fibrostenosis based on endoscopy, imaging, histopathology, functional studies, and biomarkers. We excluded studies with <10 patients. We chose fibrostenosis as the umbrella term, encompassing all definitions.RESULTSWe identified 230 studies. The four categories of fibrostenosis definitions were: (1) structural findings (stricture, rings, and/or narrowings) (n=204, 88.7%), (2) histology (n=85, 37.0%), (3) functional (functional lumen imaging probe) (n=15, 6.5%), and (4) biomarkers (n=7, 3.0%). Multiple definitions were used in 78 studies. Methods used to detect structural fibrostenosis included Eosinophilic Oesophagitis Endoscopic Reference Score fibrostenotic components, luminal diameter (endoscopy or imaging), need for dilation, and endoscopist or radiologist global impression. Methods used to detect histologic fibrostenosis included Eosinophilic Oesophagitis Histologic Scoring System lamina propria fibrosis, pathologist global impression, and basal zone hyperplasia. Methods used to detect functional fibrostenosis included distensibility and compliance.CONCLUSIONSSignificant variability exists in definitions and diagnostic methods of detection regarding fibrostenosis in eosinophilic oesophagitis. Lack of agreement hampers progress in further investigating this complication. Development of consensus criteria is necessary to provide clarity for clinical care and research.","PeriodicalId":121,"journal":{"name":"Alimentary Pharmacology & Therapeutics","volume":"25 1","pages":""},"PeriodicalIF":7.6,"publicationDate":"2025-06-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144320380","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Twenty-Year Trends in Colectomy Rates and Advanced Therapy Prescribing in Lothian, Scotland.","authors":"Alexander T Elford,Nathan Constantine-Cooke,Phil W Jenkinson,Beatriz Gros,Nikolas Plevris,Mathew Lyons,Solomon Ong,Neil Greenlees,Victor Velasco-Pardo,Claire O'Hare,Nicholas T Ventham,Paul Henderson,David C Wilson,Shahida Din,Colin L Noble,Gareth-Rhys Jones,Ian Arnott,Charlie W Lees","doi":"10.1111/apt.70240","DOIUrl":"https://doi.org/10.1111/apt.70240","url":null,"abstract":"BACKGROUNDThe impact of advanced therapy prescribing on colectomy rates in ulcerative colitis (UC) is unknown with conflicting published evidence.AIMTo describe advanced therapy prescribing trends and colectomy rates for patients with UC in Lothian, UK between January 1st, 2004 and December 31st, 2023.METHODSWe obtained incidence and prevalence data from the Lothian IBD Registry, a rigorously validated population cohort. We report advanced therapy prescribing and colectomy data as raw numbers and annual incidence rates. We used piecewise linear regression analyses to identify temporal trends in prescription and colectomy rates.RESULTSThe prevalence of UC increased from 216 to 441 per 100,000 population in the 20 years from 2004, culminating in a total of 4115 patients with UC in 2023. We identified 720 patients who had received an advanced therapy. Prescribing of first-line advanced therapy increased from 0 in 2004 to 115 in 2023, equating to 0.00 and 2.82 per 100 patients with UC. We identified 563 patients of the prevalent UC population who had colectomy, of whom 68% were performed as emergencies. Absolute colectomy numbers decreased from 42 in 2004 to 7 in 2023, equating to 2.48 and 0.22 per 100 patients with UC. A join point in 2013 was found for both increased advanced therapy prescribing and decreased colectomy rates.CONCLUSIONThe incidence of colectomy in the UC population has decreased over time while the use of advanced therapies has greatly increased.","PeriodicalId":121,"journal":{"name":"Alimentary Pharmacology & Therapeutics","volume":"10 1","pages":""},"PeriodicalIF":7.6,"publicationDate":"2025-06-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144295809","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Letter: Methodological Gaps Undermine Conclusions on Electronic Nose Use for Colorectal Cancer Detection.","authors":"Ding Shi,Buyuan Dong","doi":"10.1111/apt.70241","DOIUrl":"https://doi.org/10.1111/apt.70241","url":null,"abstract":"","PeriodicalId":121,"journal":{"name":"Alimentary Pharmacology & Therapeutics","volume":"598 1","pages":""},"PeriodicalIF":7.6,"publicationDate":"2025-06-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144295810","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Editorial: Shooting in the Dark-The Problem With Empiric Antispasmodics for Abdominal Pain in Inflammatory Bowel Disease.","authors":"Jane Lim,Ali Rezaie","doi":"10.1111/apt.70218","DOIUrl":"https://doi.org/10.1111/apt.70218","url":null,"abstract":"","PeriodicalId":121,"journal":{"name":"Alimentary Pharmacology & Therapeutics","volume":"51 1","pages":""},"PeriodicalIF":7.6,"publicationDate":"2025-06-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144295807","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Letter: Methodological Gaps Undermine Conclusions on Electronic Nose Use for Colorectal Cancer Detection-Authors' Reply.","authors":"Milou L M van Riswijk,Peter D Siersema","doi":"10.1111/apt.70243","DOIUrl":"https://doi.org/10.1111/apt.70243","url":null,"abstract":"","PeriodicalId":121,"journal":{"name":"Alimentary Pharmacology & Therapeutics","volume":"33 1","pages":""},"PeriodicalIF":7.6,"publicationDate":"2025-06-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144295812","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}